慢性心力衰竭患者的血腺水平增加
1First Department of Medicine, Osaka University School of Medicine, Suita, Japan.
Circulation
|March 18, 1997
概括
慢性心力衰竭患者的血腺水平升高,无论原因如何. 这些增加与心力衰竭的严重程度相关,这表明腺的补偿作用.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
背景情况:
- 氨酸以其心脏保护作用而闻名.
- 血腺水平在慢性心力衰竭中的作用尚不清楚.
研究的目的:
- 在患有慢性心力衰竭的患者中检查血腺水平.
- 为了确定腺水平是否与心力衰竭的严重程度或病因相关.
主要方法:
- 分析了71名慢性心力衰竭患者.
- 患者根据心力衰竭的原因和纽约心脏协会的类别进行分类.
- 血腺水平与64名健康对照人进行了比较.
主要成果:
- 与对照组 (62 +/- 3 nmol/L) 相比,缺血性 (218 +/- 23 nmol/L) 和非缺血性 (211 +/- 21 nmol/L) 心力衰竭患者的血腺水平显著更高.
- 增加的腺水平与慢性心力衰竭的严重程度相关.
结论:
- 慢性心力衰竭患者的系统血腺水平增加.
- 增加的腺可能代表内源性补偿机制对心力衰竭中的细胞损伤.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


